Our standard
Evidence before product
Most microbiome supplements are sold on species names and general promises. Rhealiz applies the opposite standard: the one used in clinical research. This page describes that standard, with primary sources.
Three rules we apply
- 01
The strain, not the species
“Lactobacillus rhamnosus” is a species name. “Lactobacillus rhamnosus GG” is a precise strain — the one actually tested in trials. Results obtained with one strain do not transfer to another strain of the same species. A label without the full strain designation cannot be connected to any study at all.
- 02
The population, not “everyone”
The same organism can help in one population and do nothing in another. A result in children does not carry over to adults; a result in intensive care says nothing about a healthy person. Any evidence cited must say who it was obtained in.
- 03
The primary endpoint, not the abstract's conclusion
A clinical trial pre-specifies its primary endpoint. That is what the trial is judged on — not a favourable subgroup, not the closing sentence of the abstract. We read trials on their pre-specified primary endpoint.
One example: one strain, three answers
Lactobacillus rhamnosus GG is the most-studied probiotic strain in the world. The same evidence, read population by population, gives three different answers:
| Population and question | Study design | Primary-endpoint result | Source |
|---|---|---|---|
| Children — antibiotic-associated diarrhoea | Meta-analysis, 5 RCTs, n=445 (children) | Risk reduced (RR 0.48; 95% CI 0.26–0.89), moderate quality | Szajewska & Kołodziej, Aliment Pharmacol Ther 2015 doi:10.1111/apt.13404 |
| Adults — antibiotic-associated diarrhoea | Same meta-analysis, 6 RCTs, n=863 (adults) | Not significant (RR 0.48; 95% CI 0.20–1.15), low quality | Szajewska & Kołodziej, Aliment Pharmacol Ther 2015 doi:10.1111/apt.13404 |
| Critically ill adults, ICU — ventilator-associated pneumonia | Double-blind placebo RCT, n=2,653, 44 ICUs | Primary endpoint missed (21.9% vs 21.3%; HR 1.03). All 20 secondary outcomes null | Johnstone et al., JAMA 2021 doi:10.1001/jama.2021.13355 |
A bottle saying “contains Lactobacillus rhamnosus” communicates none of this. That gap between label and evidence is exactly what our standard exists to close.
What this commits Rhealiz to
- Every strain selected for a Rhealiz programme must have published human data, identified by its full strain designation.
- The strain-to-study mapping will be documented and published at launch, source by source, DOI by DOI.
- Where evidence is weak or absent, we will say so. A clear line between emerging research and established evidence is part of the product.
This page describes scientific publications; it is not medical advice and makes no health claim about any Rhealiz product. The product and programme are under development.
Last updated : 2026-08-09